- Home
- ACRS vs POWW Comparison
ACRS vs POWW Comparison
Compare ACRS & POWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- POWW
- Stock Information
- Founded
- ACRS 2012
- POWW 1990
- Country
- ACRS United States
- POWW United States
- Employees
- ACRS N/A
- POWW N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- POWW Ordnance And Accessories
- Sector
- ACRS Health Care
- POWW Industrials
- Exchange
- ACRS Nasdaq
- POWW Nasdaq
- Market Cap
- ACRS 132.0M
- POWW 154.4M
- IPO Year
- ACRS 2015
- POWW N/A
- Fundamental
- Price
- ACRS $2.72
- POWW $0.98
- Analyst Decision
- ACRS Strong Buy
- POWW Hold
- Analyst Count
- ACRS 5
- POWW 1
- Target Price
- ACRS $8.75
- POWW $1.50
- AVG Volume (30 Days)
- ACRS 1.1M
- POWW 784.7K
- Earning Date
- ACRS 11-06-2024
- POWW 02-06-2025
- Dividend Yield
- ACRS N/A
- POWW N/A
- EPS Growth
- ACRS N/A
- POWW N/A
- EPS
- ACRS N/A
- POWW N/A
- Revenue
- ACRS $27,079,000.00
- POWW $135,498,023.00
- Revenue This Year
- ACRS N/A
- POWW $5.67
- Revenue Next Year
- ACRS N/A
- POWW $4.86
- P/E Ratio
- ACRS N/A
- POWW N/A
- Revenue Growth
- ACRS 26.35
- POWW N/A
- 52 Week Low
- ACRS $0.86
- POWW $0.96
- 52 Week High
- ACRS $5.17
- POWW $2.94
- Technical
- Relative Strength Index (RSI)
- ACRS 41.17
- POWW 31.89
- Support Level
- ACRS $2.91
- POWW $1.12
- Resistance Level
- ACRS $3.29
- POWW $1.08
- Average True Range (ATR)
- ACRS 0.29
- POWW 0.06
- MACD
- ACRS -0.18
- POWW -0.02
- Stochastic Oscillator
- ACRS 0.75
- POWW 11.00
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About POWW AMMO Inc.
AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.